eFFECTOR Announces Dosing of First Breast Cancer Patient with Tomivosertib in Combination with Chemotherapy Through a Grant from Stand Up To Cancer® (SU2C) Canada
November 12, 2020 08:12 ET
|
eFFECTOR Therapeutics
SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulation inhibitors (STRIs) for the treatment of cancer, today...
eFFECTOR’s Zotatifin (eFT226) Downregulates Key Oncogenic Driver Proteins Including RTKs (HER2, FGFR1 and FGFR2) Providing Single Agent Activity and Key Combination Opportunities
October 26, 2020 16:05 ET
|
eFFECTOR Therapeutics
SAN DIEGO, Oct. 26, 2020 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulation inhibitors (STRIs) for the treatment of cancer, today...
eFFECTOR Appoints Premal Patel, M.D., Ph.D., as Chief Medical Officer
October 15, 2020 08:00 ET
|
eFFECTOR Therapeutics
SAN DIEGO, Oct. 15, 2020 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today...
eFFECTOR’s Tomivosertib Demonstrates Positive Phase 2 Results for Subjects with Non-Small Cell Lung Cancer in Combination with Checkpoint Inhibitors
May 29, 2020 08:00 ET
|
eFFECTOR Therapeutics
Addition of Tomivosertib Conferred Benefit in Subjects Progressing on Checkpoint Inhibitors AloneData presented at the American Society for Clinical Oncology 2020 Virtual Scientific Program SAN DIEGO,...
eFFECTOR’s Zotatifin Demonstrates in vitro Anti-SARS-CoV-2 Activity in Independent International Study Reported in Peer-Reviewed Journal Nature
April 30, 2020 09:00 ET
|
eFFECTOR Therapeutics
SAN DIEGO, April 30, 2020 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., today announced that preliminary results from an independent preclinical study showed that oncology product candidate...
eFFECTOR’s Zotatifin (eFT226) Inhibited Tumor Growth and Caused Tumor Regression Across Diverse Receptor Tyrosine Kinase-Driven Tumor Types in Preclinical Models of Disease
April 27, 2020 08:00 ET
|
eFFECTOR Therapeutics
SAN DIEGO, April 27, 2020 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, announced...
eFFECTOR to Present During BIO CEO & Investor Conference
February 06, 2020 16:05 ET
|
eFFECTOR Therapeutics
SAN DIEGO, Feb. 06, 2020 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced that...
eFFECTOR Enters Into Agreement with Pfizer Inc. to Develop Novel First-in-Class Inhibitors of eIF4E to Treat Multiple Cancer Types
January 09, 2020 08:00 ET
|
eFFECTOR Therapeutics
SAN DIEGO, Jan. 09, 2020 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, and Pfizer Inc. (NYSE:...
eFFECTOR Therapeutics Initiates Phase 1/2 Safety and Efficacy Study of Zotatifin (eFT226) in Patients with Advanced Solid Tumor Malignancies
November 05, 2019 08:00 ET
|
eFFECTOR Therapeutics
SAN DIEGO, Nov. 05, 2019 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced the...
eFFECTOR Presents Data on its Selective Translation Regulators at AACR 2019 Annual Meeting
March 29, 2019 08:00 ET
|
eFFECTOR Therapeutics
SAN DIEGO, March 29, 2019 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced that...